Analyst consensus rating
Sutro Biopharma Analyst Rating: Strong Buy
Direct answer
Sutro Biopharma's consensus rating is Strong Buy.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $47.23.
Forecast evidence checked October 2, 2026.
Get free Sutro Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $15.68
- Average price target
- $47.23
- High price target
- $61.00
- Low price target
- $10.00
- Low target gap
- -36.2%
- Target upside
- +201.2%
- High target gap
- +289%
- Target range width
- 325.3%
- Consensus rating
- Strong Buy
- Analysts
- 13
- Evidence date
- October 2, 2026
- Valid through
- October 9, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Sutro Biopharma?
Sutro Biopharma has a verified Strong Buy consensus. The same dataset has an average price target of $47.23.
How far are Sutro Biopharma's low and high targets from the recorded price?
The low target implies -36.2%, while the high target implies +289%.
How many analysts are included in Sutro Biopharma's consensus?
The verified consensus includes 13 analysts.
How is Sutro Biopharma's target upside or downside calculated?
The average target of $47.23 is divided by the recorded price of $15.68, then one is subtracted to produce +201.2%. This does not guarantee a future return.
When was Sutro Biopharma's analyst forecast verified?
The data was verified on 2026-10-02. The dataset is valid through 2026-10-09.